共 50 条
- [41] Preoperative survivin, ERCC1, and PTEN expression in stage III non-small cell lung cancer (NSCLC) patients (pts) treated with neoadjuvant and definitive chemoradiation and association with overall survival (OS)JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Batus, MartaFidler, Mary J.Walters, Kelly KaiserPool, MarkMahon, BrettBasu, SanjibBorgia, Jeffrey AllenSher, DavidBonomi, Philip D.
- [42] Preoperative Survivin, Ercc1 And Pten Expression In Stage III Non-small Cell Lung Cancer (nsclc) Patients(pts) Treated With Neoadjuvant And Definitive Chemoradiation And Association With Overall Survival (os).JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (09) : S238 - S238Batus, M.Fidler, M.Walters, K. KaiserPool, M.Mahon, B.Basu, S.Borgia, J. A.Sher, D.Bonomi, P. D.
- [43] Real-world (RW) treatment patterns and survival outcomes by PD-L1 expression in stage IV non-squamous (nsq) non-small cell lung cancer (NSCLC): A retrospective analysis of the UK National Cancer Registry Database (NCRAS)ANNALS OF ONCOLOGY, 2024, 35 : S855 - S855Gomes, F.Lee, H.Ingleby, F.Bouajila, I.Sudhapalli, P.Chaparova, E.Zheng, Y.
- [44] Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapyJournal of Cancer Research and Clinical Oncology, 2023, 149 : 1755 - 1763J. Nicholas BodorJessica R. BaumanElizabeth A. HandorfEric A. RossMargie L. ClapperJoseph Treat
- [45] Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapyJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (05) : 1755 - 1763Bodor, J. NicholasBauman, Jessica R.Handorf, Elizabeth A.Ross, Eric A.Clapper, Margie L.Treat, Joseph
- [46] Association of baseline plasma D-dimer and platelets with progression-free survival in patients with stage IV non-small cell lung cancer treated with anti-PD-1 antibodyTRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (11)Pang, BoyueWang, JingWang, JingZhang, JialiRen, XiubaoHan, Ying
- [47] OVERALL SURVIVAL (OS) AND PROGRESSION FREE SURVIVAL (PFS) RESULTS FOR A RANDOMIZED PHASE 2 TRIAL OF IPILIMUMAB (IPI) AND PACLITAXEL/CARBOPLATIN (P/C) IN FIRST-LINE STAGE IIIB/IV NON-SMALL CELL LUNG CANCER (NSCLC)ANNALS OF ONCOLOGY, 2010, 21 : 126 - 126Lynch, T. J., Jr.Neal, J.Bondarenko, I.Luft, A.Serwatowski, P.Barlesi, F.Chacko, R.Sebastian, M.Cuillerot, J.Reck, M.
- [48] Myeloid immunosuppressive state as a predictor of rapidly progressive phenotype and poor survival in advanced non-small cell lung cancer (NSCLC) patients treated with PD-1/PD-L1 inhibitors.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Lau, Sally C. M.Le, Lisa W.Chan, Sze Wah SamuelSmith, Elliot CharlesRyan, MalcolmBrown, M. CatherineHueniken, KatrinaEng, LawsonPatel, DevalbenChen, RuiQiZer, AlonaSung, Mike RuBradbury, Penelope AnnOhashi, Pamela S.Shepherd, Frances A.Tsao, Ming SoundLeighl, Natasha B.Liu, GeoffreySacher, Adrian G.
- [49] Randomized phase II study of pembrolizumab (P) alone versus pegilodecakin (PEG) in combination with P as first-line (1L) therapy in patients (pts) with stage IV non-small cell lung cancer (NSCLC) with high PD-L1 expression (CYPRESS 1).JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Spigel, David R.Shum, Merrill KingmanSchneider, Jeffrey GaryJotte, Robert M.Eisenstein, Jennifer L.Bhanderi, Viralkumar K.Konduri, KartikHung, AnnieHozak, Rebecca R.Ferry, David RaymondGandhi, LeenaChao, Bo H.Rybkin, Igor I.
- [50] Correlating the effects of VeriStrat result, anti-PD1 therapy, and neutrophil-to-lymphocyte ratio (NLR) on progression-free survival (PFS) in patients with stage IV non-small cell lung cancer (NSCLC).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Randall, MeganBasu, SanjibBatus, MartaBorgia, Jeffrey AllenBonomi, Philip D.Fidler, Mary J.